文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

重组人粒细胞集落刺激因子治疗不明原因复发性流产患者的疗效与安全性:多中心、随机、双盲、对照试验方案

Efficacy and safety of recombinant human granulocyte colony-stimulating factor in patients with unexplained recurrent pregnancy loss: a protocol for a multicenter, randomized, double-blind, controlled trial.
PubMed 文献 · Trials · 2025-07-14

本研究为多中心、随机、双盲、安慰剂对照试验方案,计划纳入528例不明原因复发性流产中国女性,比较妊娠早期至孕10周+0天皮下注射G-CSF 150 μg隔日一次与安慰剂的疗效与安全性。主要终点为胎儿存活至24周,次要终点包括早期流产、临床确认妊娠、持续妊娠、胎儿存活至28周、异位妊娠、早产、死产及妊娠并发症。

要点

  • 试验计划纳入528例uRPL患者,G-CSF组与安慰剂组各264例。
  • G-CSF 150 μg皮下注射隔日一次,自确认早孕后开始至孕10周+0天。
  • 主要终点为胎儿存活至24周,所有参与者均接受地屈孕酮和阿司匹林支持治疗。

核心结论

  • 本试验旨在为G-CSF治疗uRPL的疗效与安全性提供高质量证据,尤其针对现有数据有限的中国人群。
  • 研究结果可能支持循证推荐并为治疗选择有限且存在争议的人群提供治疗决策依据。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照临床试验方案,计划纳入528例 eligible 参与者。
  • 参与者随机分配至试验组(n=264,G-CSF 150 μg皮下注射隔日一次)或对照组(n=264,安慰剂)。
  • 治疗自确认早期妊娠后开始,至妊娠10周+0天结束。
  • 所有参与者同时接受地屈孕酮和阿司匹林作为支持治疗。

主要发现

  • 主要终点为胎儿存活至24周。
  • 次要终点包括早期流产、临床确认妊娠、持续妊娠、胎儿存活至28周、异位妊娠、早产、死产及妊娠并发症(子痫前期、妊娠期糖尿病、HELLP综合征、胎盘早剥)。
  • 将基于研究中心(4个中心)、年龄、流产次数和体重指数探索亚组效应。

关键数值与推荐

  • uRPL定义为无明确原因发生两次或以上妊娠丢失,影响约1-2%尝试怀孕的女性。
  • 试验组G-CSF 150 μg皮下注射隔日一次,对照组安慰剂,自确认早孕后开始至孕10周+0天。
  • 所有参与者均接受地屈孕酮和阿司匹林支持治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unexplained recurrent pregnancy loss (uRPL), defined as the loss of two or more pregnancies without an identified cause, affects approximately 1-2% of women trying to conceive. Emerging evidence suggests that an imbalance in maternal-fetal immunological tolerance may play a key role in its pathogenesis. Granulocyte colony-stimulating factor (G-CSF), a glycosylated polypeptide chain cell growth factor, has shown promise in improving pregnancy outcomes in uRPL, although findings from previous clinical trials are inconsistent. High-quality, adequately powered studies are urgently needed to determine its clinical utility. This study aims to evaluate the efficacy and safety of G-CSF in Chinese women with uRPL, providing a more theoretical basis for clinical practice. METHODS: A randomized, double-blind, placebo-controlled, multicenter clinical trial will enroll 528 eligible participants, assigned to test group (n = 264, G-CSF 150 μg, subcutaneously every other day) and control group (n = 264, placebo), starting after confirmation of early pregnancy and ending at 10 weeks + 0 days of gestation. All participants will also receive dydrogesterone and aspirin as supportive care. The primary endpoint is fetal survival to 24 weeks, and secondary endpoints are early pregnancy loss, clinically confirmed pregnancy, ongoing pregnancy, fetal survival to 28 weeks, ectopic pregnancy, preterm birth, stillbirth, and pregnancy complications (preeclampsia, gestational diabetes mellitus, HELLP syndrome, placental abruption). The trial will also explore subgroup effects based on research centers (4 centers), age, number of pregnancy losses, and body mass index. DISCUSSION: This trial aims to provide high-quality evidence on the efficacy and safety of G-CSF in the treatment of uRPL, particularly in the Chinese population where existing data are limited. The findings may support evidence-based recommendations and inform treatment decisions in a population where therapeutic options remain limited and controversial. TRIAL REGISTRATION: ChiCTR2300077436. Prospectively registered on 2023-11-08.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mu F, Cai Z, Du L, et al. Efficacy and safety of recombinant human granulocyte colony-stimulating factor in patients with unexplained recurrent pregnancy loss: a protocol for a multicenter, randomized, double-blind, controlled trial. Trials. 2025. PMID: 40660339. doi:10.1186/s13063-025-08951-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。